CX-5461 potentiates imatinib-induced apoptosis in K562 cells by stimulating KIF1B expression (Part 3)

The selective RNA polymerase I inhibitor CX-5461 has been shown to be effective in treating some types of leukemic disorders. Emerging evidence suggests that combined treatments with CX-5461 and other chemotherapeutic agents may achieve enhanced effectiveness as compared to monotherapies. In the present study, we tested whether CX-5461 could potentiate the effect of imatinib in the human chronic myeloid leukemia cell line K562. Cells were divided into 3 treatment groups (with 3 independent biological replications in each group): control, imatinib (100 nM for 48 hr) alone, and imatinib+CX-5461 (100 nM for 48 hr). Genome-wide mRNA sequencing was performed.

选择性RNA聚合酶I（RNA polymerase I）抑制剂CX-5461已被证实可有效治疗部分白血病性疾病。新近涌现的证据表明，将CX-5461与其他化疗药物联合给药，相较单一疗法，可获得更优的治疗效果。本研究探讨了CX-5461能否增强伊马替尼（imatinib）对人慢性髓系白血病细胞系K562的作用效果。实验将细胞分为3个处理组，每组设置3次独立生物学重复：对照组、单用伊马替尼组（100 nM，处理48小时）、伊马替尼联合CX-5461组（100 nM，处理48小时）。随后对各组样本开展了全基因组mRNA测序（genome-wide mRNA sequencing）。